Cutaneous leishmaniasis: Review Article

May Y. Al-Ma'amouri

doi:10.55544/jrasb.2.2.7

Authors

May Y. Al-Ma'amouri Medical Technology Institute Al-Mansour, Middle Technical University, IRAQ.

DOI:

https://doi.org/10.55544/jrasb.2.2.7

Keywords:

Cutaneous Leishmaniasis (CL)

Abstract

Leishmaniasis is a protozoal infection caused by a number of different species in the Leishmania genus. Sandflies are the vectors for the transmission of these protozoa to humans. When macrophages are triggered into a leishmanicidal state, a clinical recovery occurs. In particular, the T-helper cell type 1 (Th1) response is responsible for this, and it is also responsible for preventing the recurrence of latent chronic infection. Regardless of the disease's clinical manifestation, antimonial drugs are the treatment of choice. Amphotericin B is the second-best treatment option. This study focuses on the pathology and treatment of cutaneous leishmaniasis.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

S. H. Ralston, I. D. Penman, M. W. J. Strachan, and R. Hobson, Davidson’s Principles and Practice of Medicine E-Book. Elsevier Health Sciences, 2018.

M. S. Bailey and D. N. J. Lockwood, “Cutaneous leishmaniasis,” Clin. Dermatol., vol. 25, no. 2, pp. 203–211, 2007.

Z. Bezie et al., “Common skin diseases,” Int Dev, vol. 13, pp. 200–204, 2005.

A. O. Jawabreh, “RISK ASSESSMENT OF CUTANEOUS LEISHMANIASIS IN JERICHO CITY-PALESTINE.” Al-Quds University-Palestine, 1999.

H. J. C. de Vries, S. H. Reedijk, and H. D. F. H. Schallig, “Cutaneous leishmaniasis: recent developments in diagnosis and management,” Am. J. Clin. Dermatol., vol. 16, no. 2, pp. 99–109, 2015.

P. Minodier and P. Parola, “Cutaneous leishmaniasis treatment,” Travel Med. Infect. Dis., vol. 5, no. 3, pp. 150–158, 2007.

A. Kumar, “Transmission of leishmaniasis from human to other vertebrates: a rapid zooanthroponotic evolution,” Int. Microbiol., vol. 22, no. 3, pp. 399–401, 2019.

F. E. G. Cox, Modern parasitology: a textbook of parasitology. John Wiley & Sons, 2009.

N. C. Hepburn, “Cutaneous leishmaniasis: an overview.,” J. Postgrad. Med., vol. 49, no. 1, p. 50, 2003.

D. R. Mehregan, A. H. Mehregan, and D. A. Mehregan, “Histologic diagnosis of cutaneous leishmaniasis,” Clin. Dermatol., vol. 17, no. 3, pp. 297–304, 1999.

F. Y. Liew and C. A. O’donnell, “Immunology of leishmaniasis,” Adv. Parasitol., vol. 32, pp. 161–259, 1993.

P. Scott and F. O. Novais, “Cutaneous leishmaniasis: immune responses in protection and pathogenesis,” Nat. Rev. Immunol., vol. 16, no. 9, pp. 581–592, 2016.

P. Scott, “Immunologic memory in cutaneous leishmaniasis,” Cell. Microbiol., vol. 7, no. 12, pp. 1707–1713, 2005.

A. Schubach et al., “Detection of Leishmania DNA by polymerase chain reaction in scars of treated human patients,” J. Infect. Dis., vol. 178, no. 3, pp. 911–914, 1998.

P. de O. Camera et al., “Haematogenous dissemination of Leishmania (Viannia) braziliensis in human American tegumentary leishmaniasis,” Trans. R. Soc. Trop. Med. Hyg., vol. 100, no. 12, pp. 1112–1117, 2006.

G. W. Wortmann, N. E. Aronson, R. S. Miller, D. Blazes, and C. N. Oster, “Cutaneous leishmaniasis following local trauma: a clinical pearl,” Clin. Infect. Dis., vol. 31, no. 1, pp. 199–201, 2000.

R. Reithinger, J.-C. Dujardin, H. Louzir, C. Pirmez, B. Alexander, and S. Brooker, “Cutaneous leishmaniasis,” Lancet Infect. Dis., vol. 7, no. 9, pp. 581–596, 2007.

K. Wajihullah and H. A. Zakai, “Epidemiology, pathology and treatment of cutaneous leishmaniasis in Taif region of Saudi Arabia,” Iran. J. Parasitol., vol. 9, no. 3, p. 365, 2014.

A. Martins, J. A. Barreto, J. R. P. Lauris, and A. C. G. Martins, “P.(2014). American tegumentary leishmaniasis: Correlations among immunological, histopathological and clinical parameters,” An. Bras. Dermatol., vol. 89, no. 1, pp. 52–58.

L. P. Carvalho, S. Passos, A. Schriefer, and E. M. Carvalho, “Protective and pathologic immune responses in human tegumentary leishmaniasis,” Front. Immunol., vol. 3, p. 301, 2012.

A. Giudice et al., “Macrophages participate in host protection and the disease pathology associated with Leishmania braziliensisinfection,” BMC Infect. Dis., vol. 12, no. 1, pp. 1–9, 2012.

A. Ribeiro-de-Jesus, R. P. de Almeida, H. Lessa, O. Bacellar, and E. M. Carvalho, “Cytokine profile and pathology in human leishmaniasis,” Brazilian J. Med. Biol. Res., vol. 31, pp. 143–148, 1998.

M. Brown, M. Noursadeghi, J. Boyle, and R. N. Davidson, “Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis,” Br. J. Dermatol., vol. 153, no. 1, pp. 203–205, 2005.

Jawetz, Melinck, and Adelbergs book p733,28th edition.